"Antimalarials" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585)
| Descriptor ID |
D000962
|
| MeSH Number(s) |
D27.505.954.122.250.100.085
|
| Concept/Terms |
Antimalarials- Antimalarials
- Antimalarial Agents
- Agents, Antimalarial
- Antimalarial Drugs
- Drugs, Antimalarial
- Anti-Malarials
- Anti Malarials
|
Below are MeSH descriptors whose meaning is more general than "Antimalarials".
Below are MeSH descriptors whose meaning is more specific than "Antimalarials".
This graph shows the total number of publications written about "Antimalarials" by people in this website by year, and whether "Antimalarials" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 2 | 0 | 2 |
| 2000 | 2 | 0 | 2 |
| 2001 | 4 | 0 | 4 |
| 2002 | 2 | 0 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 2 | 1 | 3 |
| 2005 | 2 | 2 | 4 |
| 2006 | 5 | 0 | 5 |
| 2007 | 0 | 3 | 3 |
| 2008 | 3 | 1 | 4 |
| 2009 | 2 | 0 | 2 |
| 2010 | 3 | 1 | 4 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 2 | 2 | 4 |
| 2014 | 1 | 1 | 2 |
| 2015 | 2 | 2 | 4 |
| 2016 | 2 | 1 | 3 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antimalarials" by people in Profiles.
-
New Transmission-Selective Antimalarial Agents through Hit-to-Lead Optimization of 2-([1,1'-Biphenyl]-4-carboxamido)benzoic Acid Derivatives. Chembiochem. 2022 Nov 04; 23(21):e202200427.
-
Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2022 11; 81(11):1541-1548.
-
Comparative pharmacokinetics and tissue distribution of primaquine enantiomers in mice. Malar J. 2022 Feb 05; 21(1):33.
-
Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care Res (Hoboken). 2021 12; 73(12):1789-1795.
-
Novel Synthetic Polyamines Have Potent Antimalarial Activities in vitro and in vivo by Decreasing Intracellular Spermidine and Spermine Concentrations. Front Cell Infect Microbiol. 2019; 9:9.
-
Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial. Trials. 2018 Dec 20; 19(1):694.
-
Bioactive products from singlet oxygen photooxygenation of cannabinoids. Eur J Med Chem. 2018 Jan 01; 143:983-996.
-
Across state lines: Fulminant Babesia microti infection in a liver transplant recipient. Transpl Infect Dis. 2017 Oct; 19(5).
-
Repurposing the anti-malarial drug, quinacrine: new anti-colitis properties. Oncotarget. 2016 Aug 16; 7(33):52928-52939.
-
Artesunate inhibits type I interferon-induced production of macrophage migration inhibitory factor in patients with systemic lupus erythematosus. Lupus. 2017 Jan; 26(1):62-72.